CD274 and neoplasm: Many predictive biomarkers are found to be associated with treatment responses to immune checkpoint blockade therapies, including tumor mutational load, DNA mismatch repair deficiency, the composition of the gut microbiome, the intensity of CD8+ cell infiltration, and intratumoral PDL1 expression.